TG Therapeutics Inc. (TGTX)
| Bid | 38.94 |
| Market Cap | 7.31B |
| Revenue (ttm) | 329M |
| Net Income (ttm) | 23.38M |
| EPS (ttm) | 0.15 |
| PE Ratio (ttm) | 306.83 |
| Forward PE | 23.62 |
| Analyst | Buy |
| Ask | 52.32 |
| Volume | 1,376,895 |
| Avg. Volume (20D) | 2,712,334 |
| Open | 45.48 |
| Previous Close | 45.51 |
| Day's Range | 44.13 - 46.33 |
| 52-Week Range | 15.16 - 46.40 |
| Beta | 2.14 |
About TGTX
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbra...
Analyst Forecast
According to 6 analyst ratings, the average rating for TGTX stock is "Buy." The 12-month stock price forecast is $41.5, which is a decrease of -9.83% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago · seekingalpha.com
TG Therapeutics: Bright Outlook, Bolstered By Briumvi And Upcoming TrialsTG Therapeutics is rated a strong buy with a 12-month price target of $44, driven by positive Briumvi sales and future trial plans. Briumvi exceeded FY 2024 sales forecasts and is expected to surpass ...
1 month ago · seekingalpha.com
TG Therapeutics: Exciting Briumvi Performance, Looking To Re-EnterTGTX's Briumvi, despite initial struggles, has shown strong performance by consistently beating earnings estimates, even with competition from Roche's Zunovo. Briumvi's competitive advantages include ...
